Transcept Pharmaceuticals is a specialty pharmaceutical company engaged in developing and commercializing proprietary products that address therapeutic needs in the field of neuroscience. Intermezzo (zolpidem tartrate) sublingual tablet C-IV is the company’s first FDA-approved product. Commercialization and development rights for Intermezzo in the U.S. are held by Purdue. Transcept is presently conducting a Phase 2 study of the investigational product TO-2061 in patients suffering from obsessive-compulsive disorder. For more information, visit the company’s Web site at www.transcept.com.

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory, and related services to public and private companies across multiple sectors and regions. Rodman also provides research, sales, and trading services. According to Sagient Research Systems, Rodman has been ranked the #1 Placement Agent in terms of the aggregate number of PIPE and RD financing transactions completed every year since 2005. For more information on Rodman & Renshaw, visit www.rodmanandrenshaw.com.

Let us hear your thoughts below: